Bayer ADR Securities Litigation Settlement
This settlement is closed to new claims — the deadline was October 16, 2025. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Bayer is settling a securities class action lawsuit related to its publicly traded American Depositary Receipts. The court preliminarily approved the settlement on June 27, 2025, and authorized it to be distributed to potential class members.
Do you qualify?
All persons or entities that purchased or otherwise acquired Bayer's publicly traded American Depositary Receipts between May 23, 2016 and July 6, 2020.
How to file
Submit a claim form by October 16, 2025. You can file online through the settlement website. Class members must submit a claim form to receive any payment and will release all Related Plaintiffs' Claims against the defendants.
Common questions
- What is the claim deadline for the Bayer ADR Securities Litigation Settlement?
- This settlement is closed to new claims — the deadline was October 16, 2025. Once a claim deadline passes you generally forfeit your share, even if you qualified.
- Is the Bayer ADR Securities Litigation Settlement notice real, or a scam?
- Claims are filed at bayeradrsecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the Bayer ADR Securities Litigation Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for October 30, 2025; no payments can be issued before a settlement receives final approval.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Revance Securities Settlement
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Not yet determinable; depends on number of valid claims submitted
Biogen Securities Litigation Settlement
Biogen Inc. investors have settled a securities litigation case for $18.9 million in cash. The settlement resolves claims related to purchases of Biogen common stock during the specified class period.
NJ Bureau of Securities Settlement with Credit Suisse
Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.
Stitch Fix Securities Litigation Settlement
Stitch Fix, Inc. is settling a securities class action lawsuit without admitting wrongdoing. The Lead Plaintiffs alleged that Stitch Fix issued misleading statements about its business, and shareholders who purchased the stock during the class period suffered damages as a result.